Carrot Fertility vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Carrot Fertility is a global fertility benefits platform offering employers customizable coverage for IVF, adoption, surrogacy, menopause, and low-cost medication through 50+ countries.
About
Carrot Fertility is a global fertility and family-forming benefits company founded in 2016 by Tammy Sun, raising over $100M to build the most comprehensive employer fertility benefits platform globally. The company offers employers a highly customizable benefits program covering IVF, egg freezing, donor services, adoption, gestational surrogacy, menopause care, and gender-affirming family building across 50+ countries. Carrot operates a digital-first model that connects members with clinical resources, care navigation, and financial support rather than owning a proprietary clinic network. The platform integrates with leading fertility clinics and medication pharmacies to provide members access to vetted care at competitive prices, including a Carrot Rx program that sources fertility medications at significantly below-retail prices. Carrot serves hundreds of employers including major technology companies, professional services firms, and global corporations that want inclusive fertility benefits covering all paths to parenthood. The company competes with Progyny and Kindbody in the US employer fertility benefits market while leading in global coverage for international employers with diverse workforces across multiple countries.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.